Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To compare the efficacy of 3 dose levels of ARRY-438162 (10 mg BID, 40 mg QD, and 20 mg BID) versus placebo, administered over 12 weeks for the treatment of the signs and symptoms of patients with RA. • To determine the American College of Rheumatology 20% (ACR20) best response rate at Week 12 of patients treated with any well-tolerated dose. • To evaluate the safety of ARRY-438162 in patients with active RA on stable doses of methotrexate (≥10 mg ≤ 25 mg) for ≥ 6 weeks.
Critère d'inclusion
- Active Rheumatoid Arthritis incompletely responsive to methotrexate